The drug exists, but it's not yet accessible to most people
In Brazil, the expiration of a pharmaceutical patent has opened a door long awaited by millions living with type 2 diabetes: the country's health regulator Anvisa has approved Ozivy, the first domestically produced semaglutide injection, manufactured by EMS. The drug shares its active mechanism with the globally coveted Ozempic, yet arrives as a synthetic alternative at a moment when market forces and national production capacity may finally bend the curve of affordability. What remains unresolved — pricing, public system access, and the broader pipeline of competitors — reminds us that regulatory approval is only the first threshold in the longer journey from laboratory to patient.
- Millions of Brazilians dependent on costly imported semaglutide now have a domestically manufactured alternative after Anvisa cleared Ozivy for type 2 diabetes treatment.
- The approval arrives precisely as Ozempic's patent protection expires, triggering a race among pharmaceutical competitors and raising urgent questions about who will benefit first and most.
- Strict cold-chain requirements — refrigeration between 2 and 8°C at all times — introduce logistical hurdles that could limit Ozivy's reach in regions with fragile infrastructure.
- The final price remains hostage to CMED regulatory approval, though market expectations point to a significant undercut of Ozempic's roughly R$1,000 price tag.
- Access through the SUS public health network is far from guaranteed, requiring a separate Conitec evaluation with no announced timeline, leaving the most vulnerable patients in a prolonged waiting room.
- Six more semaglutide-based medications are already queued for Anvisa review, signaling that Ozivy is less an endpoint than the opening move in a sweeping reshaping of Brazil's diabetes and weight-loss drug market.
Brazil's health regulator Anvisa approved Ozivy this week — the first semaglutide injection manufactured entirely within the country — marking a significant shift in the landscape of diabetes treatment. Produced by EMS, one of Brazil's largest pharmaceutical companies, the drug arrives precisely as Ozempic's patent protection has expired, creating conditions for cheaper domestic alternatives to emerge.
Ozivy and Ozempic share semaglutide as their active ingredient, but differ in origin: Ozempic uses a biologically derived compound, while Ozivy relies on a synthetic version. Both are administered as weekly injections for adults with type 2 diabetes inadequately managed by diet and exercise alone. One practical distinction stands out — Ozivy requires continuous refrigeration between 2 and 8°C, a stricter storage demand than its predecessor.
The question of cost remains open. Pricing must still be approved by the CMED, Brazil's pharmaceutical pricing authority, but the market broadly expects Ozivy to come in well below Ozempic's current price of around R$1,000, given domestic production and the expired patent. When exactly that price will be set remains unknown.
Access through the SUS public health system presents a separate and less certain path. Inclusion would require a distinct evaluation by the Conitec commission, with no timeline announced and no guarantee of approval for public distribution.
Ozivy is not alone in the pipeline. Anvisa confirmed that six additional semaglutide-based medications — generics and biosimilars — are currently under technical review, suggesting that Brazil's pharmaceutical market is on the cusp of meaningful competition in this category. For now, Ozivy stands as the first concrete result of that transformation: a domestically made option that promises greater affordability, even as the most consequential details of price and public access remain to be written.
Brazil's health regulator has cleared the way for a domestic competitor to one of the world's most sought-after diabetes and weight-loss medications. The Anvisa approved Ozivy this week, marking the first semaglutide injection manufactured entirely within the country. The drug comes from EMS, a major Brazilian pharmaceutical company, and arrives at a moment when the original Ozempic's patent protection has just expired—opening the door for cheaper alternatives to flood the market.
Ozivy and Ozempic share the same active ingredient, semaglutide, but they are not identical. The original uses a biologically derived version of the compound, while Ozivy relies on a synthetically manufactured one. Both are administered as weekly injections for adults whose type 2 diabetes has not responded adequately to diet and exercise alone. The distinction matters less for efficacy than it does for logistics: Ozivy demands strict temperature control, requiring refrigeration between 2 and 8 degrees Celsius at all times, before and after treatment begins. Ozempic, by contrast, offers more flexibility in storage.
The question everyone is asking—how much will it cost?—remains unanswered. The final price depends on approval from Brazil's pharmaceutical pricing regulator, the CMED. Yet the market consensus is clear: because Ozempic's patent has expired and Ozivy is made domestically, it should undercut the original's current price of roughly 1,000 reais. How much cheaper, and when that price will be set, are still unknowns.
Another major uncertainty surrounds access through Brazil's public health system. For Ozivy to reach the SUS—the country's universal healthcare network—it must clear a separate evaluation by the Conitec, the commission responsible for deciding which new technologies the government will fund. No timeline for that review has been announced, and there is no guarantee the medication will be approved for public distribution at all.
The approval of Ozivy is not an isolated event. The Anvisa confirmed that six additional semaglutide-based medications, whether generic or biosimilar versions, are currently under technical review. The pipeline suggests that Brazil's pharmaceutical market is about to experience significant competition in this category, driven by the expiration of Ozempic's patent protection and growing demand for weight-loss and diabetes treatments. For now, Ozivy represents the first tangible result of that shift—a domestically made option that promises affordability, though the specifics of price and public availability remain to be determined.
Citas Notables
The market expects Ozivy to cost less than the original Ozempic due to the expired patent and domestic production— Market analysis cited in Anvisa approval
La Conversación del Hearth Otra perspectiva de la historia
Why does it matter that Ozivy uses synthetic semaglutide instead of the biological version?
The active ingredient works the same way in your body either way. The difference is in how it's made and what that means for storage and cost. Synthetic is cheaper to manufacture at scale, which is why people expect Ozivy to undercut Ozempic.
But the refrigeration requirement seems like a real problem for patients.
It is. Ozempic is more forgiving—you can leave it out longer. Ozivy demands constant cold storage. That's a genuine inconvenience, especially in a country with unreliable electricity in some regions.
Will poor Brazilians actually be able to afford this, or is it just another drug for the wealthy?
That depends entirely on two things: what the CMED sets as the price, and whether Conitec decides to fund it through the SUS. Right now, neither has happened. The drug exists, it's approved, but it's not yet accessible to most people.
Why are there six more semaglutide drugs waiting in line?
Because the patent wall just came down. Every pharmaceutical company sees an opportunity. Once one generic or biosimilar gets approved, the floodgates open. Competition drives prices down, which is good for patients—eventually.
What's the real story here—is this a win for Brazilian patients or just a corporate opportunity?
Both, probably. It's a win that a Brazilian company can manufacture this at all. But the win only matters if people can actually buy it and use it. That part is still being written.